ORBRODA
DEAD

Serial Number

98472325

Owner

BRISTOL-MYERS SQUIBB COMPANY

Attorney

Marilyn F. Kelly

Filing Date

Mar 28, 2024

Add to watchlist:

No watchlists yet
View on USPTO

ORBRODA Trademark

Serial Number: 98472325

ORBRODA is a trademark filed by BRISTOL-MYERS SQUIBB COMPANY on March 28, 2024. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently no longer active.

Owner Contact Info

BRISTOL-MYERS SQUIBB COMPANY (4,799 trademarks)

NEW YORK, NY 10154

Entity Type: 03

Trademark Details

Filing Date

March 28, 2024

Registration Date

Not Registered

Published for Opposition

February 18, 2025

Goods & Services

Pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer, cytokine inhibitory drugs; Pharmaceutical preparations for human use that modulate the immune system; Pharmaceutical and biological preparations for human use for immunotherapy, namely T Cell therapy; Pharmaceutical and biological preparations for human use, namely, stem cells for medical or clinical use; Pharmaceutical preparations for human use for the treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use, namely, antivirals for treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use, namely, monoclonal antibodies for medical use; Pharmaceutical preparations for human use, namely, for the treatment of neuropsychiatric disorders; Pharmaceutical preparations for human use, namely, therapeutic radiopharmaceutical preparations for the treatment of cancer and solid tumors, diagnostic radiopharmaceutical preparations, diagnostic agents, preparations and substances for medical purposes; Pharmaceutical preparations for human use, namely, radiopharmaceutical imaging and detection agents for diagnosing and monitoring cancer, radio-isotope markers for therapeutic or diagnostic use.

Filing History

ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Nov 17, 2025 MAB6
ABANDONMENT - NO USE STATEMENT FILED
Nov 17, 2025 ABN6
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Apr 15, 2025 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Feb 18, 2025 NPUB
PUBLISHED FOR OPPOSITION
Feb 18, 2025 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Feb 12, 2025 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Jan 28, 2025 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jan 14, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jan 14, 2025 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jan 14, 2025 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Oct 16, 2024 GNRN
NON-FINAL ACTION E-MAILED
Oct 16, 2024 GNRT
NON-FINAL ACTION WRITTEN
Oct 16, 2024 CNRT
ASSIGNED TO EXAMINER
Oct 8, 2024 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jul 8, 2024 NWOS
NEW APPLICATION ENTERED
Mar 28, 2024 NWAP